Anti-TMEM219 Antibodies Blocking IGFBP3 in Colorectal Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for colorectal cancer, particularly colitis-associated colorectal cancer, are ineffective and often associated with adverse effects, low tumor-specific selectivity, and high resistance, necessitating a more targeted therapeutic approach.
Innovation Solution
Development of an anti-TMEM219 antibody that inhibits the binding of IGFBP3 to the TMEM219 receptor, reducing tumor density and progression in colorectal cancer models.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments for colorectal cancer are used, then treatment coverage is broad, but tumor-specific selectivity is low and adverse effects increase
Solution Approach 1:
The patent uses anti-TMEM219 antibodies as intermediary agents that specifically target the TMEM219 receptor overexpressed on colorectal cancer cells. This intermediary approach allows selective binding to tumor cells while sparing healthy tissues, thereby improving tumor-specific selectivity and reducing adverse effects compared to conventional non-specific chemotherapy agents
Solution Approach 2:
The invention exploits the local quality difference in TMEM219 receptor expression between tumor and normal tissues. By designing antibodies that specifically recognize and bind to the overexpressed TMEM219 on colorectal cancer cells, the treatment achieves localized action at the tumor site, improving selectivity and minimizing systemic adverse effects
2Reliability
If conventional chemotherapy is applied, then tumor progression is slowed, but resistance develops rapidly
Solution Approach 1:
The patent extracts and targets a specific molecular mechanism (TMEM219 receptor-IGFBP3 interaction) that is critical for colorectal cancer cell survival and proliferation. By blocking this specific pathway with highly specific antibodies, the treatment achieves sustained efficacy without the broad non-specific effects that lead to rapid resistance development in conventional chemotherapy
Solution Approach 2:
The invention changes the therapeutic parameter from non-specific cytotoxicity to specific receptor-mediated inhibition. The anti-TMEM219 antibodies modulate the tumor microenvironment and inhibit cancer cell growth through a specific molecular pathway, creating a more sustainable treatment effect that delays resistance development
3Productivity
If surgical removal is performed, then immediate tumor reduction is achieved, but adjuvant therapy is still required for advanced stages
Solution Approach 1:
The patent applies preliminary action by using anti-TMEM219 antibodies to reduce tumor burden and inhibit progression before adjuvant therapy is administered. This pre-treatment approach can potentially reduce the complexity of subsequent adjuvant regimens by eliminating or reducing residual disease, making the overall treatment less complex
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The anti-TMEM219 antibody significantly reduces tumor density and size, offering a promising treatment option with potential for combined therapy to enhance efficacy.
Implementation Method 1
an antibody that binds to TMEM219 receptor or antigen binding fragment thereof
Data Source
Figure 1
Figure 2
Figure 3~4
AI summary
The present invention relates to antibodies or antigen binding fragments thereof that bind to TMEM219 receptor for use in the treatment and/or prevention of colorectal cancer. Pharmaceutical compositions comprising said antibody for use in the treatment and/or prevention of colorectal cancer are also an object of the invention.